Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?

This study has been completed.
Sponsor:
Information provided by:
Sorlandet Hospital HF
ClinicalTrials.gov Identifier:
NCT00202709
First received: September 12, 2005
Last updated: July 27, 2011
Last verified: September 2005

September 12, 2005
July 27, 2011
May 2002
August 2003   (final data collection date for primary outcome measure)
Global symptom index (gsi) on the Symptom checklist 90 revised (SCL-90-R) [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
Global symptom index (gsi) on the Symptom checklist 90 revised (SCL-90-R)
Complete list of historical versions of study NCT00202709 on ClinicalTrials.gov Archive Site
  • Davidson Trauma Scale [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
  • Liebowitz Social Anxiety Scale [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
  • Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
  • Fear Questionnaire (FQ) [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
  • Sheehan Disability Scale [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
  • Davidson Trauma Scale
  • Liebowitz Social Anxiety Scale
  • Hospital Anxiety and Depression Scale (HADS)
  • Fear Questionnaire (FQ)
  • Sheehan Disability Scale
Not Provided
Not Provided
 
Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?
Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group.

The purpose of this study is to find out if Thought Field Therapy has effect on certain anxiety disorders; agoraphobia, social phobia, and post traumatic stress disorder (PTSD).

Thought Field Therapy is an alternative treatment method that has been shown, by casuistic reports, to give good results when applied for anxiety disorders. In this study 52 patients, with one or more of the diagnoses agoraphobia, social phobia and/or PTSD, where randomized to either treatment with TFT or a wait list. The treatment group all got treatment in one week. 2 1/2 months later both the treatment group and the control group were tested on the same items as before the treatment started. After this evaluation phase the control group got the same treatment as the treatment or study group. Both groups were evaluated 3 and 12 months after treatment, the study group also 6 months after treatment. 4 patients were omitted because they changed groups. The study were performed from May 2002 until June 2003.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Agoraphobia
  • Social Phobia
  • PTSD
Behavioral: Thought Field Therapy (TFT)
Treatment with TFT twice in one week
Other Name: Wait list control
  • Experimental: Thought Field Therapy (TFT)
    Treatment with TFT, first one hour, then 1/2 hour.
    Intervention: Behavioral: Thought Field Therapy (TFT)
  • No Intervention: Wait list control
Irgens A, Dammen T, Nysæter TE, Hoffart A. Thought Field Therapy (TFT) as a treatment for anxiety symptoms: a randomized controlled trial. Explore (NY). 2012 Nov;8(6):331-8. doi: 10.1016/j.explore.2012.08.002.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
52
August 2003
August 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • One or more of the study diagnoses agoraphobia, social phobia and/or PTSD

Exclusion Criteria:

  • Ongoing psychosis
  • Ongoing serious drug problems
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
NCT00202709
SSHF-AUIR-1
No
Audun Irgens, MD, Sorlandet sykehus HF
Sorlandet Hospital HF
Not Provided
Principal Investigator: Audun C Irgens, MD Sorlandet Hospital HF
Sorlandet Hospital HF
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP